Anti-BRAF V600E (Hu) aus Kaninchen (RM8) – unkonj.

References for BRAF V600E Mutant antibody [RM8]

Martin AM et al. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. J Neuropathol Exp Neurol. (2020), 10.1093/jnen/nlz119. WB; Human. Read more (PubMed: 31819973)
Shirsat PM et al. Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study. J Oral Maxillofac Pathol. (2018), 10.4103/jomfp.JOMFP_174_17. IHC; Human. Read more (PubMed: 30651680)
Usman H et al.t Result Analysis of BRAF V600E Gene Mutation Using Molecular and Immunohistochemistry Detection in Acral Malignant Melanoma. Asian Pacific Journal of Cancer Care. (2018), 10.31557/APJCC.2018.3.3.43. IHC; Human. (WAOCP)
Hansen C et al. Nanoswitch-linked immunosorbent assay (NLISA) for fast, sensitive, and specific protein detection. Proc Natl Acad Sci USA. (2017), 10.1073/pnas.1708148114. ELISA, WB; Human. PubMed: 28893984)
Krishnamurthy A et al. Clinical utility of immunohistochemistry using the novel anti-BRAF V600E antibody (clone RM8) for detection of the BRAF V600E mutant protein in papillary thyroid cancers. Int J Mol ImmunoOncol. (2018) 10.18203/issn.2456-3994.IntJMolImmunoOncol20180471. IHC-P; Human. Read more (IJMIO: ISSN: 2456-3994)
Gouravan S et al. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. Int J Mol Sci. (2018) 10.3390/ijms19040969. WB; Human.(PubMed: 29570692)
Yang H et al. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene (2017) 10.1038/onc.2016.526. WB; Human.(PubMed: 28263969)
ZM Shaban et al. BRAFV600E Mutation in Gliomas in Iraqi Patients Immunohistochemical Study. ijcocr (2017) 10.11648/j.ijcocr.20170206.11. IHC; Human.